News
Old saying about prostate cancer not true when it’s metastatic
“Most patients with metastatic prostate cancer die from it, rather than other possible causes of death,” researcher says.
News
FDA warns again about robotic mastectomy, breaks new ground
The new advisory comes 4 weeks after a Medscape Medical News exclusive story on a set of clinical trials recently underway using RAS devices for...
News
FDA OKs belzutifan for cancers tied to von Hippel–Lindau disease
The treatment was approved for patients with von Hippel–Lindau disease undergoing treatment for renal cell...
News
‘Routine’ use of focal therapy for prostate cancer in next 5 years
Focal therapy rejects one-size-fits-all medicine in favor of individualized treatment.
News
One in three cancer articles on social media has wrong info
Physician says misleading information online may be harmful to patients.
News
Bone drugs for prostate cancer may result in survival benefit
Retrospective study shows the addition of bone resorption inhibitors to abiraterone, plus prednisolone, may lengthen survival.
News
The robot comes to mastectomy, but cancer outcomes data not attached
Clinical trials are underway in the United States to explore the use of robotic surgical devices for nipple-sparing mastectomy, but investigators...
News
In the previous year, 70% of oncologists reported sexual harassment
“The survey’s recall period [about harassment] was in the previous 12 months. The respondents weren’t reflecting on a lifetime of events.”
News
FDA OKs nivolumab after surgery for esophageal or GEJ cancer: Practice-changing use of immunotherapy
A 1-year course of adjuvant nivolumab did not negatively impact patient-reported quality of life, the trialists reported.
News
FDA okays upfront pembro for advanced HER2+ gastric cancer
The accelerated approval is for first-line use in combination with other agents for locally advanced unresectable or metastatic HER2-positive...
News
FDA approves new immunotherapy for endometrial cancer
The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair.